Abstract Background The Infectious Diseases Society of America (IDSA) is committed to
providing up-to-date guidance on the treatment of antimicrobial-resistant (AMR) infections …

Cefiderocol appears promising, as it can overcome most β-lactam resistance mechanisms
(including β-lactamases, porin mutations, and efflux pumps). Resistance is uncommon …

Stenotrophomonas maltophilia is a non-fermenting, Gram-negative bacillus that has
emerged as an opportunistic nosocomial pathogen. Its intrinsic multidrug resistance makes …

Antimicrobial resistance continues to increase globally and treatment of difficult-to-treat
(DTT) infections, mostly associated with carbapenem-resistant (CR) Pseudomonas …

The emergence and spread of bacteria resistant to commonly used antibiotics poses a
critical threat to modern medical practice. Multiple classes of bacterial efflux pump systems …

Staphylococcus aureus generates biofilms during many chronic human infections, which
contributes to its growth and persistence in the host. Multiple genes and pathways …

Cefiderocol (FDC) is a siderophore cephalosporin now recognized as a new weapon in the
treatment of difficult-to-treat-resistant (DTR) Gram-negative pathogens, including …

Staphylococcus aureus is a facultative intracellular pathogen of human macrophages, which
facilitates chronic infection. The genotypes, pathways, and mutations influencing that …

Purpose Cefiderocol susceptibility testing (AST) represents an open challenge for clinical
microbiology. Herein, we evaluated the performance of the UMIC® Cefiderocol broth …

Cefiderocol, a novel siderophore cephalosporin, demonstrates promising in vitro activity
against multidrug-resistant Gram-negative bacteria, including carbapenemase-producing …